MRK Stock Recent News
MRK LATEST HEADLINES
Jared Holz, Mizuho, joins 'Fast Money' to talk his playbook on recent biotech movers.
Merck (MRK) closed at $115.25 in the latest trading session, marking a +0.47% move from the prior day.
Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.
Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped Merck's blockbuster Keytruda.
Sunday, Summit Therapeutics Inc. SMMT released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc.
Summit Therapeutics said its Ivonescimab treatment reduced the risk of disease progression or death by 49% compared with the market leader.
AbbVie is a Dividend King with solid growth prospects. Merck's looming patent cliff isn't as alarming as it might seem.
The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.
Venerable Coca-Cola has increased dividends for more than six decades. Merck's lifesaving treatments aren't affected by economic cycles.
MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.